Next Generation Immunotherapies Market Growth Projections 2024-2034: DelveInsight Analysis | GlaxoSmithKline, Roche, Regeneron Pharma, Boehringer Ingelheim, MacroGenics, MereoBiopharma, Hubao Biopharm

The Key Next Generation Immunotherapies Companies in the market include - GlaxoSmithKline, Roche, Regeneron Pharmaceuticals, Boehringer Ingelheim, MacroGenics, MereoBiopharma, Hubao Biopharm, Shanghai Huaota Biopharmaceutical Co., Ltd., Kymab Limited, Sanofi, GlaxoSmithKline, Novartis Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, AstraZeneca, Hoffmann-La Roche, Immunomic Therapeutics, Inc., Indaptus Therapeutics, Inc, Merck KGaA, Menarini Group, and others.

DelveInsight's "Next Generation Immunotherapies Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Next Generation Immunotherapies, historical and forecasted epidemiology as well as the Next Generation Immunotherapies market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Next Generation Immunotherapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Next Generation Immunotherapies Market Forecast [https://www.delveinsight.com/sample-request/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Next Generation Immunotherapies Market Report:

*
The Next Generation Immunotherapies market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In March 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech firm specializing in Microbiome Ecosystem Therapies Trademark (MET) to improve cancer patient survival through immune modulation, is set to present new preclinical findings at the upcoming American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025, in Chicago, Illinois.

*
In February 2025, UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on advancing treatments for urothelial and specialty cancers, has announced the expansion of its oncology pipeline with the acquisition of next-generation oncolytic virus assets, ICVB-1042, from IconOVir Bio, Inc. (IconOVir). Additionally, UroGen has entered into several strategic research partnerships to evaluate how its proprietary RTGel technology can enhance the clinical performance of various immunotherapies, including improving drug dwell time to boost treatment outcomes.

*
In November 2024, Recent developments in the clinical trial of BH3120, a novel immunotherapy co-developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, were showcased at a prominent international academic event, garnering notable interest within the immunotherapy community. Hanmi revealed that the research findings and clinical updates on BH3120 were shared during a poster presentation at the Society for Immunotherapy of Cancer (SITC) conference.

*
The Next Generation Immunotherapies in development target a variety of immune pathways, with key targets including LAG-3, TIGIT, NKG2A, CD73, TIM-3, B7-H3, A2A receptor, FAK, CD47-SIRP receptor, CSF-1, and several others.

*
According to the study by Atkins et al. (2022), there are over 80,000 new instances of renal cell carcinoma (RCC) and nearly 14,000 fatalities from RCC per year in the United States

*
The American Cancer Society predicts that in 2022, there will be roughly 287,850 new instances of invasive breast cancer in women identified in the United States

*
The Skin Cancer Foundation estimates that in 2022, there will be roughly 197,700 new instances of melanoma identified in the US, of which 97,920 cases will be in situ and 99,780 cases will be invasive, entering the epidermis into the dermis. Moreover, 57,180 men and 42,600 women will experience invasive cases

*
Prostate cancer is the most prevalent cancer in men, according to the Gustave Rossy Cancer Centre, with more than 70,000 new cases each year in France. This cancer often progresses slowly. It may be absolutely silent or the source of urinary symptoms like frequent micturition or trouble urinating

*
Key Next Generation Immunotherapies Companies: GlaxoSmithKline, Roche, Regeneron Pharmaceuticals, Boehringer Ingelheim, MacroGenics, MereoBiopharma, Hubao Biopharm, Shanghai Huaota Biopharmaceutical Co., Ltd., Kymab Limited, Sanofi, Alpine Immune Sciences, Inc., Xencor, Inc., Shanghai EpimAb Biotherapeutics Co., Ltd., GlaxoSmithKline, Novartis Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, AstraZeneca, Hoffmann-La Roche, Immunomic Therapeutics, Inc., Indaptus Therapeutics, Inc, Merck KGaA, Menarini Group, and others

*
Key Next Generation Immunotherapies Therapies: cobolimab (GSK-4069889), tiragolumab (RG-6058), Fianlimab (REGN-3767), Tebotelimab (MGD013), Ezabenlimab (BI-754091), MGC 018, Etigilimab, INCAGN02385, HB-0036, HB0036, KY1044 and atezolizumab, AZD2936, ALPN-101, Tepotinib, XmAb22841, EMB-02, TSR-022, MBG453, BMS-986213, Pemigatinib, AZD7789, RO7247669, ITI-1001, Decoy20, Avelumab, MEN1611, and others

*
Mesothelioma was diagnosed in 1,290 men and 340 women in Germany in 2022, according to The Robert Koch Institute (2022). A minor drop in age-standardized incidence rates is now visible more than 20 years after Germany banned the processing of asbestos, but no discernible decline in total mortality rates is yet visible

*
The Next Generation Immunotherapies market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Next Generation Immunotherapies pipeline products will significantly revolutionize the Next Generation Immunotherapies market dynamics.

Next Generation Immunotherapies Overview

Next-generation immunotherapies are advanced treatments designed to enhance the immune system's ability to detect and destroy cancer cells more effectively. These therapies go beyond traditional immunotherapy by using cutting-edge approaches such as CAR T-cell therapy, immune checkpoint inhibitors, and cancer vaccines. They focus on improving the immune response, increasing specificity to target cancer cells, and reducing side effects. Next-generation immunotherapies hold promise for treating a wider range of cancers and are being developed to overcome resistance to existing treatments and offer long-term protection against tumor recurrence.

Get a Free sample for the Next Generation Immunotherapies Market Report:

https://www.delveinsight.com/report-store/next-generation-immunotherapies-market [https://www.delveinsight.com/report-store/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Next Generation Immunotherapies Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Next Generation Immunotherapies Epidemiology Segmentation:

The Next Generation Immunotherapies market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Next Generation Immunotherapies

*
Prevalent Cases of Next Generation Immunotherapies by severity

*
Gender-specific Prevalence of Next Generation Immunotherapies

*
Diagnosed Cases of Episodic and Chronic Next Generation Immunotherapies

Download the report to understand which factors are driving Next Generation Immunotherapies epidemiology trends @ Next Generation Immunotherapies Epidemiology Forecast [https://www.delveinsight.com/sample-request/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Next Generation Immunotherapies Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Next Generation Immunotherapies market or expected to get launched during the study period. The analysis covers Next Generation Immunotherapies market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Next Generation Immunotherapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Next Generation Immunotherapies Therapies and Key Companies

*
Fianlimab (REGN-3767): Regeneron Pharmaceuticals

*
Tebotelimab (MGD013): MacroGenics

*
Ezabenlimab (BI-754091): Boehringer Ingelheim

*
cobolimab (GSK-4069889): GlaxoSmithKline

*
tiragolumab (RG-6058): Roche

Discover more about therapies set to grab major Next Generation Immunotherapies market share @ Next Generation Immunotherapies Treatment Market [https://www.delveinsight.com/sample-request/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Next Generation Immunotherapies Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Next Generation Immunotherapies Companies: GlaxoSmithKline, Roche, Regeneron Pharmaceuticals, Boehringer Ingelheim, MacroGenics, MereoBiopharma, Hubao Biopharm, Shanghai Huaota Biopharmaceutical Co., Ltd., Kymab Limited, Sanofi, Alpine Immune Sciences, Inc., Xencor, Inc., Shanghai EpimAb Biotherapeutics Co., Ltd., GlaxoSmithKline, Novartis Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, AstraZeneca, Hoffmann-La Roche, Immunomic Therapeutics, Inc., Indaptus Therapeutics, Inc, Merck KGaA, Menarini Group, and others

*
Key Next Generation Immunotherapies Therapies: cobolimab (GSK-4069889), tiragolumab (RG-6058), Fianlimab (REGN-3767), Tebotelimab (MGD013), Ezabenlimab (BI-754091), MGC 018, Etigilimab, INCAGN02385, HB-0036, HB0036, KY1044 and atezolizumab, AZD2936, ALPN-101, Tepotinib, XmAb22841, EMB-02, TSR-022, MBG453, BMS-986213, Pemigatinib, AZD7789, RO7247669, ITI-1001, Decoy20, Avelumab, MEN1611, and others

*
Next Generation Immunotherapies Therapeutic Assessment: Next Generation Immunotherapies current marketed and Next Generation Immunotherapies emerging therapies

*
Next Generation Immunotherapies Market Dynamics: Next Generation Immunotherapies market drivers and Next Generation Immunotherapies market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Next Generation Immunotherapies Unmet Needs, KOL's views, Analyst's views, Next Generation Immunotherapies Market Access and Reimbursement

To know more about Next Generation Immunotherapies companies working in the treatment market, visit @ Next Generation Immunotherapies Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Next Generation Immunotherapies Market Report Introduction

2. Executive Summary for Next Generation Immunotherapies

3. SWOT analysis of Next Generation Immunotherapies

4. Next Generation Immunotherapies Patient Share (%) Overview at a Glance

5. Next Generation Immunotherapies Market Overview at a Glance

6. Next Generation Immunotherapies Disease Background and Overview

7. Next Generation Immunotherapies Epidemiology and Patient Population

8. Country-Specific Patient Population of Next Generation Immunotherapies

9. Next Generation Immunotherapies Current Treatment and Medical Practices

10. Next Generation Immunotherapies Unmet Needs

11. Next Generation Immunotherapies Emerging Therapies

12. Next Generation Immunotherapies Market Outlook

13. Country-Wise Next Generation Immunotherapies Market Analysis (2020-2034)

14. Next Generation Immunotherapies Market Access and Reimbursement of Therapies

15. Next Generation Immunotherapies Market Drivers

16. Next Generation Immunotherapies Market Barriers

17. Next Generation Immunotherapies Appendix

18. Next Generation Immunotherapies Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=next-generation-immunotherapies-market-growth-projections-20242034-delveinsight-analysis-glaxosmithkline-roche-regeneron-pharma-boehringer-ingelheim-macrogenics-mereobiopharma-hubao-biopharm]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.